Sickle Cell Anemia Successfully Treated in India with BMT

Patient’s Name: Malakai Abinya
Country: Kenya
Condition: Sickle Cell Anemia
Treatment: Half-Matched Bone Marrow Transplant (BMT)
Doctor: Dr. Vikas Dua
Hospital: Fortis Memorial Research Institute (FMRI), Gurgaon

Malakai Abinya, a young boy from Kenya, had been suffering from Sickle Cell Anemia, an inherited blood disorder that significantly affected his daily life. Frequent health complications and repeated hospital visits made it difficult for him to live a normal childhood. His parents were determined to find a permanent and affordable treatment solution.

After extensive online research, the family discovered that India offers advanced medical care for sickle cell anemia at an affordable cost. They contacted our team to understand the treatment options available in India. After carefully reviewing Malakai’s medical reports, we arranged a video consultation with Dr. Vikas Dua, a leading hematologist at Fortis Memorial Research Institute, Gurgaon.

During the consultation, Dr. Vikas explained the bone marrow transplant procedure, treatment duration, and necessary precautions. After understanding the process clearly, Malakai traveled to India with his parents for treatment. Our team assisted the family at every step, including medical visa support, airport pickup, accommodation near the hospital, and complete logistical coordination.

All required diagnostic tests were completed, and the half-matched bone marrow transplant was successfully performed, with Malakai’s father serving as the donor. The family stayed in India for approximately six months to complete treatment and recovery under close medical supervision.

Sharing their experience, Malakai’s mother expressed heartfelt gratitude, thanking Medsurge India, Dr. Vikas Dua, and the entire FMRI team for their care, guidance, and constant support throughout the journey.

After completing recovery, the family returned to Kenya with relief and renewed hope. We wish Malakai a healthy, happy, and bright future ahead.